

October 7, 2022,

## Clonit announces the acquisition of Experteam.

Clonit srl, active in the field of Molecular Diagnostics with a strong know-how in the development, production and distribution of innovative reagents for the infectious and genetic diseases, less than three months after the entry of Equita Smart Capital ELTIF, a private fund equity from Equita Capital SGR, completes the acquisition of 100% of Experteam, a company that since 1996 has been providing the market with customized solutions in the field of Molecular Diagnostics.

Based in the VEGA Science & Technology Park in Venice, Experteam is active in the production and distribution of high quality products in the diagnostics of genetic diseases (infertility, degenerative diseases and oncology) and in human, environmental and food virology and microbiology.

The acquisition - which represents a further step in the creation of a leading group in the *in vitro* diagnostics field - is aimed to strength Clonit's role in the molecular diagnostics market, expanding its technical-scientific skills and its portfolio of products and services.

**Carlo Roccio, President of Clonit**, commented: "Thanks to many years of experience in the diagnostic R&D field, Experteam has acquired a long-standing relationships with its customers. We are thrilled to be able to collaborate and expand our product portfolio and distribution channels, thus supporting our customers in the rapidly growing Molecular Diagnostics Market".

**Angelo De Bortoli, Chief Executive Officer of Experteam**, added: "Experteam is proud to become part of a group where the different scientific, commercial and management skills will determine the development of a company at the top of the new challenge of molecular diagnostics, able to compete with the main competitors globally".

To complete the transaction, CLONIT, coordinated by **Dario Russo (Chief Executive Officer)**, availed of the support of **Gabriele Arcuri, Gianmarco Scialpi, Martina Antonelli, Riccardo Dore, Angelica Pertusio** and **Matteo Licini** of the **DLA Piper** for the legal part, of **Dr. Salvatore Salzano** and **Dr. Giovanni Vitiello** of **Minerva Corporate Finance** for the financial advisor and financial due diligence activities and of **Dr. Fabio Marinsalta** of **Studio Marinsalta** for the tax due diligence activities.

For the completion of the operation, the Experteam, coordinated by **Angelo De Bortoli** and **Federica Schiavon**, availed of the collaboration of **Dr. Franco Castro** of **Studio Castro e Scremin** in Venice.

